Carotid artery plaque uptake of $^{11}$C-PK11195 inversely correlates with circulating monocytes and classical CD14$^+$CD16$^-$ monocytes expressing HLA-DR

Enrico Ammirati$^{a,b,*}$, Francesco Moroni$^a$,$^*$, Marco Magnoni$^a$, Elena Busnardo$^c$, Simona Di Terlizzi$^d$, Chiara Villa$^d$, Federico Sizzano$^e$, Isabella Scotti$^f$, Alessio Palini$^g$, Luca Presotto$^g$, Valentino Bettinardi$^c$, Pietro Spagnolo$^c$, Francesca Besana$^c$, Luigi Gianolli$^c$, Ornella E. Rimoldi$^h$, Paolo G. Camici$^{a,**}$

---

**A R T I C L E  I N F O**

Article history:
Received 18 April 2018
Received in revised form 27 August 2018
Accepted 16 September 2018
Available online xxxx

Keywords:
Carotid plaque
$^{11}$C-PK11195 uptake
Classical monocytes
Positron emission tomography
Atherosclerosis

---

**A B S T R A C T**

Background: We explored the relation between blood concentrations of monocyte/lymphocyte subsets and carotid artery plaque macrophage content, measured by positron emission tomography (PET) with $^{11}$C-PK11195.

Methods and results: In 9 patients with carotid plaques we performed $^{11}$C-PK11195-PET/computed tomography angiography imaging and measurement of absolute concentrations and frequencies of circulating monocytes and T-cell subsets. Plaque standardized uptake value (SUV) for $^{11}$C-PK11195 was negatively correlated with concentrations of total monocytes ($r = -0.58, p = 0.05$) and CD14$^+$CD16$^-$HLA-DR$^+$ classical subset ($r = -0.82, p = 0.005$). These correlations hold true also in relation to plaque target to background ratio. No correlation was observed between plaque SUV and CD3$^+$T lymphocytes, CD4$^+$T lymphocytes nor with activated CD3$^+$CD4$^+$T cells expressing HLA-DR.

Conclusions: We first demonstrated a reduction in the absolute concentration of monocytes and particularly in classical monocytes expressing HLA-DR in the presence of an increased uptake of $^{11}$C-PK11195 in carotid plaques. The present work, despite being a pilot study comprising only a small number of subjects provides new insights in the search for specific cellular biomarkers with potential diagnostic and prognostic value in patients with a known carotid plaque.

© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

---

1. Introduction

Monocytes are among the first cells to be recruited into dysfunctional arterial walls, and are involved in atherosclerotic plaque formation and development [1]. Their contribution spans from secretion of inflammatory mediators to local differentiation into lesional macrophages [2], that make up a large proportion of atherosclerotic plaque cell constituents [3]. Activated macrophages have been demonstrated in vulnerable carotid plaques [4,5]. $^{11}$C-PK11195 is a selective ligand for the translocator protein (18 kDa) (TSPO), which is highly expressed in activated cells of the mononuclear phagocyte lineage [6]. Hybrid imaging with positron emission tomography and computed tomography angiography (PET/CTA) using $^{11}$C-PK11195 detects and quantifies vascular inflammation [7,8], and discriminates between vulnerable and non-vulnerable atherosclerotic lesions within the carotid arteries [9]. We recently demonstrated an inverse correlation between plaque neovascularization, an index of plaque vulnerability, and blood concentrations of both pro-inflammatory CD14$^+$CD16$^-$ classical monocytes and activated CD4$^+$HLA-DR$^+$T cells in asymptomatic patients with moderate carotid plaques [10,11]. Whether the reduction of circulating classical monocytes is due to a potential redistribution of these cells...
types into active lesions remains to be explored. In this proof of principle study, we sought to explore the relation between peripheral blood concentrations of classical monocyte subsets and carotid artery plaque macrophage content, measured by PET/CTA with $^{11}$C-PK11195.

2. Methods

2.1. Study design and population

The population of the study consisted of 9 patients with carotid plaques referred for routine carotid ultrasound evaluation (8 asymptomatic subjects, 1 with a previous history of ischemic stroke). The study was approved by the Ethics Committee of the San Raffaele Institute and all patients signed a written consent. This substudy is part of the IMaging Della PLAcca Carotidea (IMPLAC) study, ClinicalTrials.gov registration number was NCT03333330 and EudraCT number was 2012-000648-83.

2.2. Flow cytometry

Absolute concentrations of circulating monocytes and T-cell subsets were assessed by flow cytometry on a LSRFortessa Flow Cytometer (BD Biosciences) equipped with 5 lasers and standard optics. Whole blood was collected on the same day of the ultrasonographic evaluation using EDTA-anticoagulated vacutainer tubes. The samples were stained and analyzed within 24 h of collection. CD3 and CD4 were used to identify CD4$^+$ T cells. CD14 and CD16 were used to identify classical, intermediate and non-classical monocyte subsets as previously described following the classification of the International Union of Immunologic Societies [4,12]: classical CD14$^{++}$CD16$^-$ monocytes; intermediate CD14$^+$CD16$^+$; non-classical CD14$^+$CD16$^-$ (representative case in Fig. 1). HLA-DR was used as a marker of cellular activation. Absolute monocytes/T-cells concentration was obtained with the aid of Flow-Count beads (Beckman Coulter) as previously described [10]. Frequencies of cellular subsets were also reported as percentage of the total number of monocytes for monocyte subsets. Similarly, frequencies were calculated for lymphocytes subsets.

2.3. $^{11}$C-PK11195-PET/CTA imaging

$^{11}$C-PK11195-PET/CTA imaging of the carotid arteries was performed according to the protocol previously described by our group.

Fig. 1. Monocyte subsets identified by flow cytometry in a representative patient. Gating strategy used to identify monocytes based on forward and orthogonal scatter; then differential identification of monocyte subsets based on surface markers CD14 (antibody: PE-Cy7, M5E2, BD-Pharmingen), and CD16 (antibody: APC, B73.1, BD Pharmingen). Classical monocytes are CD14$^+$CD16$^-$; intermediate monocytes are CD14$^+$CD16$^+$; and non-classical monocytes are CD14$^+$CD16$^-$.

using a 64-slice CT scanner (VCT Lightspeed, GE Healthcare, USA) administering non-ionic, iso-osmolar contrast iodixanol (Visipaque 320; GE) [9].

2.4. Brain Magnetic resonance imaging

Asymptomatic patients (n = 8) underwent a brain MRI using a 1.5 Tesla scanner (ACHIEVA Philips Medical Systems) to assess the presence of silent white matter hyperintensities (WMHs). The protocol that was used has been previously described [13].

2.5. Statistical analysis

One-way Spearman’s test was used for correlations. Correlations with p < 0.05 were considered significant. All statistical analyses were performed using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, USA).

3. Results

3.1. Patients’ characteristics

Patients’ clinical characteristics (5 men, median age 71 years, interquartile [IQR] 65–76 years) are summarized in Table 1. Patients had a median carotid stenosis of 60% (IQR 53%–70%) using European Carotid Surgery Trial (ECST) method on CTA images and a median main carotid plaque standardized uptake value (SUV) of 1.35 g/mL (IQR 0.98–1.74 g/mL) and target-to-background ratio (TBR) of 0.94 (IQR 0.87–1.01) for $^{11}$C-PK11195 (representative case is reported in Fig. 2A–C). Only 1 patient was symptomatic for ischemic stroke, whereas the other 8 subjects were asymptomatic. Nevertheless, 7 out of 8 (87.5%) asymptomatic patients presented brain WMHs, with a median number of WMH of 23 (interquartile range [Q1–Q3]: 7–56).

3.2. Correlations between $^{11}$C-PK11195 plaque uptake and circulating inflammatory cells

Plaque SUV for $^{11}$C-PK11195 was negatively correlated with circulating concentrations of total monocytes (r = −0.58, p = 0.05), and in particular with the CD14$^+$CD16$^-$ HLA-DR$^+$ classical monocytes (r = −0.82, p = 0.005, Table 2 and Fig. 2D–E). A correlation was also observed between the TBR in the main carotid artery plaques with total monocytes (r = −0.58, p = 0.05) and CD14$^+$CD16$^-$ HLA-DR$^+$ classical monocytes (r = −0.58, p = 0.05). No significant changes in the frequencies of total monocytes in relation to the whole blood count or of CD14$^+$CD16$^-$ HLA-DR$^+$ classical monocytes in relation to the total monocytes were observed (Table 2).

No correlation was observed between background SUV in the internal jugular vein and total monocytes (r = +0.05, p = 0.46) and CD14$^+$CD16$^-$ HLA-DR$^+$ classical monocytes (r = −0.23, p = 0.28) supporting the specificity of the signal observed in the plaque. Both the

Table 1

| N     | 9   |
|-------|-----|
| Sex (M/F) | 5/4 |
| Age (years) | 71 (65–76) |
| Asymptomatic/symptomatic | 8/1 |
| BMI (Kg/m$^2$) | 25 (20–28) |
| Plaque SUV (g/mL) | 1.35 (0.98–1.74) |
| Total cholesterol (mg/dL) | 172 (156–182) |
| LDL cholesterol (mg/dL) | 102 (91–112) |
| HDL cholesterol (mg/dL) | 48 (40–58) |
| Hs-CRP (mg/dL) | 1.56 (1.18–7.45) |

Clinical characteristics of the study population. Symptoms refer to previous history of cerebrovascular accidents. BMI = body mass index; SUV = standardized uptake value; LDL = low density lipoprotein; HDL = high density lipoprotein; Hs-CRP = high sensitivity C-reactive protein.
count of CD14++CD16+HLA-DR+ intermediate and CD14+CD16+HLA-DR+ non-classical monocytes negatively correlated with plaque SUV (respectively r = −0.66, p = 0.03 and r = −0.65, p = 0.03), but the correlation was not confirmed in relation with the plaque TBR (Table 2). This finding was specific for monocytes; in fact, no correlation was observed between plaque SUV and CD3+T lymphocytes, CD4+T lymphocytes nor with activated CD3+CD4+T cells expressing HLA-DR, lymphocytes nor with activated CD3+CD4+T cells expressing HLA-DR (Table 2 and Fig. 2F), that were previously found to be reduced in patients with signs of neovascularization in carotid plaques [10]. Plaque SUV of 11C-PK11195 was not associated with other patients' characteristics nor with inflammatory biomarkers (high-sensitivity C-reactive protein [hs-CRP] and interleukin-6 [IL-6] levels).

### Table 2

| Cellular populations | Plaque SUV | Plaque TBR |
|----------------------|------------|------------|
|                      | r Spearman | p | r Spearman | p |
| Total monocytes (count) | −0.58 | 0.05 | −0.58 | 0.05 |
| Monocytes/WBC (%) | 0.08 | 0.42 | −0.33 | 0.19 |
| CD14++CD16− classical (% of monocytes) | 0.57 | 0.06 | −0.10 | 0.40 |
| CD14++CD16− classical (count) | −0.25 | 0.26 | −0.47 | 0.11 |
| CD14++CD16+ intermediate (% of monocytes) | −0.05 | 0.46 | −0.20 | 0.30 |
| CD14++CD16+ intermediate (count) | −0.36 | 0.16 | −0.40 | 0.13 |
| CD14+CD16+ nonclassical (% of monocytes) | −0.48 | 0.10 | 0.12 | 0.39 |
| CD14+CD16+ nonclassical (count) | −0.73 | 0.01 | 0.01 | 0.50 |
| HLA-DR+CD14++CD16− classical (% of monocytes) | −0.50 | 0.09 | 0.18 | 0.32 |
| HLA-DR+CD14++CD16− classical (count) | −0.82 | 0.005 | −0.58 | 0.05 |
| HLA-DR+CD14++CD16+ intermediate (% of monocytes) | −0.53 | 0.07 | −0.27 | 0.23 |
| HLA-DR+CD14++CD16+ intermediate (count) | −0.66 | 0.03 | −0.38 | 0.15 |
| HLA-DR+CD14+CD16+ nonclassical (% of monocytes) | −0.17 | 0.34 | 0.28 | 0.23 |
| HLA-DR+CD14+CD16+ nonclassical (count) | −0.65 | 0.03 | 0.05 | 0.46 |
| Total lymphocytes (count) | −0.07 | 0.44 | 0.07 | 0.44 |
| Lymphocytes/WBC (%) | 0.22 | 0.29 | 0.30 | 0.22 |
| CD3+CD4+ T cells (% of lymphocytes) | 0.27 | 0.25 | 0.20 | 0.31 |
| CD3+CD4+ T cells (count) | 0.25 | 0.26 | 0.13 | 0.37 |
| HLA-DR+CD3+CD4+ T cells (% of lymphocytes) | 0.12 | 0.39 | 0.42 | 0.13 |
| HLA-DR+CD3+CD4+ T cells (count) | 0.22 | 0.29 | 0.47 | 0.10 |

In bold are underlined correlations with a p-value of 0.05 or inferior.

Fig. 2. 11C-PK11195 carotid plaque uptake and graphs summarizing the main findings of the study. Panels A–C display PET/CT hybrid imaging of a plaque located at the right carotid bifurcation in a representative patient. The plaque shows intense 11C-PK11195 uptake (white arrows). Panel D shows the significant negative correlation between plaque SUV for 11C-PK11195 and circulating total monocytes, Panel E the correlation between SUV and CD14++CD16− HLA-DR+ activated classical monocytes and Panel F the absence of correlation between plaque SUV and activated CD3+CD4+T cells expressing HLA-DR.
4. Discussion

We described for the first time the reverse correlation between total monocytes, and in particular the CD14++CD16- HLA-DR+ classical subset with the carotid plaque uptake of 11C-PK11195. 11C-PK11195 selectively marks TPSO, that is expressed by activated monocytes/macrophages. Total monocytes and CD14++CD16- HLA-DR- classical subset are decreased in patients with plaque activation measured using a novel and specific non-invasive diagnostic tool able to demonstrate the accumulation of activated mononuclear cells within atherosclerotic lesions [9]. Thus, it is not surprising that we did not observe a reverse correlation also with CD4++HLA-DR-T cells. On the contrary in a previous study, we have shown a decrease of circulating CD4++HLA-DR-T cells in patients with carotid plaques with signs of plaque vascularization measured by CEUS [11]. Finally, no association was found between plaque SUV and hs-CRP or IL-6 further supporting the concept that these markers are not sufficient to identify patients with activated plaques [18], whereas specific cellular biomarkers appear more promising.

In conclusion, positive studies investigating the relation between signs of plaque activation by means of molecular marker of inflammation (i.e. TPSO) and specific monocyte subsets are limited [18]. Thus, the present work, despite being a pilot study comprising only a small number of subjects provides new insights in the search for specific cellular biomarkers with potential diagnostic and prognostic value in patients with known carotid plaque.

Disclosures and conflict of interests

Dr. Ammirati received financial support from the “Giovane Ricercatore 2009 Grant” from Italian Health Ministry (CR-2009-1608780). Dr. Camici has served as a consultant for Laboratori Servier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

References

[1] F.K. Swirski, M. Nahrendorf, Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure, Science 339 (6116) (2013) 161–166, https://doi.org/10.1126/science.1230719 (Epub 2013/01/12, PubMed PMID: 23307733; PubMed Central PMCID: PMCPMC3891792).
[2] C. Schulz, S. Masberg, Atherosclerosis—multiple pathways to lesional macrophages, Sci. Transl. Med. 6 (239) (2014) 239ps2, https://doi.org/10.1126/scitranslmed.3008922 (Epub 2014/06/06, PubMed PMID: 24898743).
[3] R. Virmani, A.P. Burke, A. Farb, F.D. Kologole, Pathology of the vulnerable plaque, J. Am. Coll. Cardiol. 47 (Suppl. 8) (2006) CT8–8 (PubMed PMID: 16531505).
[4] C. Weber, E. Shantsila, M. Hristov, G. Caligiuri, T. Guzik, G.H. Heine, et al., Role and analysis of monocyte subsets in cardiovascular disease. Joint consensus document of the European Society of Cardiology (ESC) Working Groups “Atherosclerosis & Vascular Biology” and “Thrombosis”, Thromb. Haemost. 116 (4) (2016) 626–637, https://doi.org/10.1160/TH16-02-0091 (Epub 2016/07/15, PubMed PMID: 27412877).
[5] M. Magnoni, E. Ammirati, P.G. Camici, Non-invasive molecular imaging of vulnerable atherosclerotic plaques, Cardiovasc. Diabetol. 15 (4) (2016) 281–289, https://doi.org/10.1016/j.1016.1010.1501.004 (PubMed PMID: 25702846).
[6] P.G. Camici, O.E. Rimoldi, O. Gaemperli, P. Libby, Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque, Eur. Heart J. 33 (11) (2012) 1331–1337, https://doi.org/10.1002/eurhr.2012.07.0379 (PubMed PMID: 22070295).
[7] F. Pugliese, O. Gaemperli, A.R. Kinderleer, L. Faramarzi, J. Shalhoub, A.H. Davies, et al., Imaging of vascular inflammation with [11C]-PK11195 and positron emission tomography/computed tomography angiography, J. Am. Coll. Cardiol. 56 (8) (2010) 633–641 (PubMed PMID: 20703227; PubMed Central PMCID: PMCPMC313504).
[8] E. Ammirati, F. Moroni, P. Pedrotti, I. Scotti, M. Magnoni, E.P. Bozzolo, et al., Non-invasive imaging of vascular inflammation, Front. Immunol. 5 (2014) 399, https://doi.org/10.3389/fimmu.2014.00399 (PubMed PMID: 25183963; PubMed Central PMCID: PMCPMC413504).
[9] O. Gaemperli, J. Shalhoub, D.R. Owens, L. Faramarzi, S. Johansson, N. Fouladi, et al., Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography, Eur. Heart J. 33 (2012) 1902–1910 (PubMed PMID: 21933781).
[10] E. Ammirati, F. Moroni, M. Magnoni, S. Di Terlizzi, C. Villa, F. Sizzano, et al., Circulating CD14+ and CD14highCD16-classical monocytes are reduced in patients with signs of plaque neovascularization in the carotid artery, Atherosclerosis 255 (2016) 171–178, https://doi.org/10.1016/j.atherosclerosis.2016.10.004 (PubMed PMID: 27751005).
[11] E. Ammirati, M. Magnoni, F. Moroni, S. Di Terlizzi, I. Scotti, C. Villa, et al., Reduction of circulating HLA-DR-T cell counts correlates with increased carotid intraplaque neovascularization and atherosclerotic burden, JACC Cardiovasc. Imaging (2016) https://doi.org/10.1016/j.jcmg.2015.10.010 (PubMed PMID: 26777226).
[12] L. Ziegler-Heitbrock, P. Ancuta, S. Crowe, M. Dalod, V. Grau, G.N. Hart, et al., Nomen-clature of monocytes and dendritic cells in blood, Blood 116 (16) (2010) e74–e80, https://doi.org/10.1182/blood-2010-02-258558 (Epub 2010/07/16, PubMed PMID: 20626140).
[13] E. Ammirati, F. Moroni, M. Magnoni, M.A. Rocca, R. Messina, N. Anzalone, et al., Relation between characteristics of carotid atherosclerotic plaques and brain white matter hyperintensities in asymptomatic patients, Sci. Rep. 7 (1) (2017) 10559, https://doi.org/10.1038/s41598-017-11216-x (Epub 2017/09/07, PubMed PMID: 28874779; PubMed Central PMCID: PMCPMC5855357).
[14] F. Moroni, E. Ammirati, M. Magnoni, F. Prascenzo, M. Asselino, N. Anzalone, et al., Carotid atherosclerosis, silent ischemic brain damage and brain atrophy: a systematic review and meta-analysis, Int. J. Cardiol. 223 (2016) 681–697, https://doi.org/10.1016/j.ijcard.2016.08.234 (PubMed PMID: 27568889).
[15] F. Moroni, E. Ammirati, M.A. Rocca, M. Filigoi, M. Magnoni, P.G. Camici, Cardiovascular disease and brain health: focus on white matter hyperintensities, Int. J. Cardiol. Heart Vasc. 19 (2018) 63–69, https://doi.org/10.1016/j.ijhcv.2018.04.006 (Epub 2018/06/28, PubMed PMID: 29560087; PubMed Central PMCID: PMCPMC5016077).
[16] A.A. Patel, Y. Zhang, J.N. Fullerton, L. Boelen, A. Rongouaux, M. Magnoni, et al., The fate and lifespan of human monocyte subsets in steady state and systemic inflammation, J. Exp. Med. 214 (7) (2017) 1913–1923, https://doi.org/10.1084/jem.20170035 (Epub 2017/06/14, PubMed PMID: 2866897; PubMed Central PMCID: PMCPMC5502436).
[17] O. Hjelmgren, L. Johansson, U. Prahl, M. Gerbig, G.M. Bergstrom, A study of plaque vascularization and inflammation using quantitative contrast-enhanced US and PET/CT, Eur. J. Radiol. 83 (3) (2014) 1184–1189, https://doi.org/10.1016/j.ejrad.2014.02.013 (PubMed PMID: 24676469; PubMed Central PMCID: PMCPMC4145469).
[18] E. Ammirati, F. Moroni, G.D. Norata, M. Magnoni, P.G. Camici, Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis, Mediat. Inflamm. 2015 (2015) 718329. https://doi.org/10.1155/2015/718329 (PubMed PMID: 25906521; PubMed Central PMCID: PMCPMC4145469).